Email updates

Keep up to date with the latest news and articles from Molecular Pain and BioMed Central.

Open Access Highly Accessed Review

Moving towards supraspinal TRPV1 receptors for chronic pain relief

Enza Palazzo1*, Livio Luongo1, Vito de Novellis1,2, Liberato Berrino1,2, Francesco Rossi1,2 and Sabatino Maione1,2

Author Affiliations

1 Department of Experimental Medicine, Pharmacology Division, The Second University of Naples, Naples, Italy

2 Centro Interdipartimentale di Ricerca e Menagement, The Second University of Naples, Naples, Italy

For all author emails, please log on.

Molecular Pain 2010, 6:66 doi:10.1186/1744-8069-6-66

Published: 11 October 2010

Abstract

Transient receptor potential vanilloid type 1 (TRPV1) receptor is a non selective ligand-gated cation channel activated by capsaicin, heat, protons and endogenous lipids termed endovanilloids. As well as peripheral primary afferent neurons and dorsal root ganglia, TRPV1 receptor is also expressed in spinal and supraspinal structures such as those belonging to the endogenous antinociceptive descending pathway which is a circuitry of the supraspinal central nervous system whose task is to counteract pain. It includes periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) whose activation leads to analgesia. Such an effect is associated with a glutamate increase and the activation of OFF and inhibition of ON cell population in the rostral ventromedial medulla (RVM). Activation of the antinociceptive descending pathway via TPRV1 receptor stimulation in the PAG may be a novel strategy for producing analgesia in chronic pain. This review will summarize the more recent insights into the role of TRPV1 receptor within the antinociceptive descending pathway and its possible exploitation as a target for new pain-killer agents in chronic pain conditions, with particular emphasis on the most untreatable pain state: neuropathic pain.